Iodoform API Manufacturers

General Description:

Iodoform, identified by CAS number 75-47-8, is a notable compound with significant therapeutic applications. Iodoform is an organoiodine compound with the formula CHI3 and a tetrahedral molecular geometry. It is a relatively water-insoluble yellow solid that is chemically reactive in free-radical reactions . Due to its antimicrobial properties following topical administration, minimal levels of iodoform may be found in disinfectants and it is more primarily used for veterinary purposes. Iodoform has also been found in dental paste and root canal filling materials in combination with other intracanal medications due to its radiopacity . Since the beginning of the 20th century, iodoform has been commonly used as a healing and antiseptic dressing or powder for wounds and sores, however such clinical use to this date is limited. Iodoform is soluble in fatty acids and decomposes releasing iodine in nascent state (96,7% of iodine) when in contact with secretions or endodontic infections .

Indications:

This drug is primarily indicated for: No approved therapeutic indications. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Iodoform undergoes metabolic processing primarily in: It is expected to be oxidized to iodine . This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Iodoform are crucial for its therapeutic efficacy: Iodoform is reported to be absorbed through denuded skin, wounds or mucous membranes . The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Iodoform is an important consideration for its dosing schedule: No pharmacokinetic data available. This determines the duration of action and helps in formulating effective dosing regimens.

Protein Binding:

Iodoform exhibits a strong affinity for binding with plasma proteins: No pharmacokinetic data available. This property plays a key role in the drug's pharmacokinetics and distribution within the body.

Route of Elimination:

The elimination of Iodoform from the body primarily occurs through: No pharmacokinetic data available. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Iodoform is distributed throughout the body with a volume of distribution of: No pharmacokinetic data available. This metric indicates how extensively the drug permeates into body tissues.

Clearance:

The clearance rate of Iodoform is a critical factor in determining its safe and effective dosage: No pharmacokinetic data available. It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Iodoform exerts its therapeutic effects through: Iodoform exhibits antibacterial activities after topical application. In a comparative study of wound dressing agents, iodoform gauze exerted an antibacterial effect 3 hours after the start of bacterial growth of _E. coli_ and subsequently maintained the strong antibacterial effectiveness . A study demonstrated that direct and indirect exposure to high concentrations of iodoform induces a cytotoxic effect on cultures of macrophages and epithelial cells _in vitro_, while cell proliferation was enhanced at low concentrations of iodoform . This cytotoxic effect of iodoform in root canals may further lead to long-term local irritation to follicles of permanent successors and formation of cyst-like radiolucent defects . The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Iodoform functions by: While the mechanism of action of iodoform remains unclear, it is proposed that iodoform releases iodine, which denatures bacterial proteins by oxidation of the free iodine . Iodoform may also play a role in chemical debridement for effective necrotic wound healing and tissue damage repair via collagen fibrinolysis; upon treatment in necrotic tissue, iodoform reduced the size of the macromolecules containing collagen I in wound surface proteins . In human gingival fibroblasts _in vitro_, high concentrations of iodoform was shown to decrease the viability of macrophages and epithelial cells and reduced the secretion of _P. gingivalis_-induced TNFα . P. gingivalis is an anaerobic bacteria present in anaerobic oral niches including periapical sites and periodontal pockets . This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Iodoform belongs to the class of organic compounds known as trihalomethanes. These are organic compounds in which exactly three of the four hydrogen atoms of methane (CH4) are replaced by halogen atoms, classified under the direct parent group Trihalomethanes. This compound is a part of the Organic compounds, falling under the Organohalogen compounds superclass, and categorized within the Alkyl halides class, specifically within the Halomethanes subclass.

Categories:

Iodoform is categorized under the following therapeutic classes: Dermatologicals, Hydrocarbons, Halogenated, Medicated Dressings, Medicated Dressings With Antiinfectives, Miscellaneous Local Anti-infectives. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Experimental Properties:

Further physical and chemical characteristics of Iodoform include:

• Water Solubility: Slightly soluble
• Melting Point: 119-122
• Boiling Point: 218